Recent 8-K filings for ONCY

• July 13, 2026, 9:03 AM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Oncolytics: FDA Type D meeting in Aug; half of REO 033 sites activated, >20 patients pre-identified

  Company to hold Type D meeting with FDA in first half of August 2026 to discuss registrational design for REO 033 Part B.

• June 16, 2026, 9:05 AM ET other material materiality 0.65 positive item 8.01item 9.01

  Oncolytics secures new U.S. patent for pelareorep manufacturing through 2044; method-of-use app to 2046

  USPTO issued patent covering pelareorep manufacturing process, expected protection into 2044.

• May 4, 2026, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC

  Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.

• April 27, 2026, 7:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  Oncolytics secures FDA alignment on pivotal anal cancer study for pelareorep

  FDA agreed on a randomized controlled pivotal trial design for pelareorep in post-first-line metastatic SCAC, targeting accelerated and full approval.

• April 6, 2026, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Oncolytics Biotech enters ATM agreement for up to $75M common stock offering

  Agreement with Jefferies LLC allows sale of up to $75M in common stock at market prices.

• March 19, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Pelareorep data at AACR: 62% ORR in pancreatic cancer; TLS formation in breast cancer

  GOBLET cohort 1: 62% objective response rate in first-line mPDAC, more than double historical chemotherapy alone.

• March 2, 2026, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Oncolytics launches Phase 2 REO 033 trial in 2L RAS-mutant MSS mCRC; preliminary data expected by end of 2026

  Randomized Phase 2 study (REO 033) of pelareorep + bevacizumab + FOLFIRI vs bevacizumab + FOLFIRI in 30 patients per arm.

• February 24, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Oncolytics prioritizes SCAC and CRC registration studies; GOBLET enrollment closed

  Concluded enrollment in GOBLET gastrointestinal study; now focusing on registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC).

• February 4, 2026, 6:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Oncolytics gets FDA Fast Track for pelareorep in 2L KRAS-mutant MSS mCRC; interim data expected YE 2026

  FDA Fast Track Designation for pelareorep + bevacizumab + FOLFIRI in second-line KRAS-mutant MSS metastatic colorectal cancer.

• January 15, 2026, 6:59 PM ET leadership materiality 0.65 positive item 8.01item 9.01

  Oncolytics appoints EVP John McAdory and VP Biostatistics Yujun Wu, grants inducement awards

  John McAdory named EVP Strategy & Operations; previously VP Clinical Ops at CG Oncology (Nasdaq: CGON).

• January 12, 2026, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Oncolytics: GOBLET Cohort 4 third-line anal cancer ORR 29%; median DOR ~17 months; files new patent application

  GOBLET Cohort 4: 4/14 evaluable third-line anal cancer patients responded (ORR 29%), 2 CRs, 2 PRs; median DOR ~17 months vs historical ~10%.

Executive changes

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

13 positive 0 negative 6 neutral

source · ONCY on sec.gov